Prostate Cancer Research - Symptoms, Genetics, Screening, Treatment, Information

Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.


Prostate Cancer Research Today

Home

View Latest Issue

Information About Prostate Cancer

Books on Prostate Cancer

Advertising in Research Today

View Other Research Today Publications



Volume 4 (2007), Issue 7 (July)

  1. Main outcomes of the FRESH START trial: a sequentially tailored, diet and exercise mailed print intervention among breast and prostate cancer survivors.
    J Clin Oncol, 25(19): 2709-18. [Abstract] [Full-text]
  2. Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men.
    Int J Cancer, 121(4): 791-5. [Abstract] [Full-text]
  3. PTHrP-induced MCP-1 production by human bone marrow endothelial cells and osteoblasts promotes osteoclast differentiation and prostate cancer cell proliferation and invasion in vitro.
    Int J Cancer, 121(4): 724-33. [Abstract] [Full-text]
  4. Patterns in information strategies used by older men to understand and deal with prostate cancer: an application of the modélisation qualitative research design.
    Int J Nurs Stud, 44(6): 961-72. [Abstract] [Full-text]
  5. The role of androgen in determining differentiation and regulation of androgen receptor expression in the human prostatic epithelium transient amplifying population.
    J Cell Physiol, 212(3): 572-8. [Abstract] [Full-text]
  6. Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo.
    Int J Cancer, 121(5): 999-1008. [Abstract] [Full-text]
  7. Prostate carcinoma cells selected by long-term exposure to reduced oxygen tension show remarkable biochemical plasticity via modulation of superoxide, HIF-1alpha levels, and energy metabolism.
    J Cell Physiol, 212(3): 744-52. [Abstract] [Full-text]
  8. Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: Location, hydrolysis and 12-lipoxygenase metabolism.
    Int J Cancer, 121(5): 984-91. [Abstract] [Full-text]
  9. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial.
    J Natl Cancer Inst, 99(13): 1025-35. [Abstract] [Full-text]
  10. Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml.
    J Surg Oncol, 96(1): 54-61. [Abstract] [Full-text]
  11. Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells.
    Eur J Pharm Biopharm, 67(1): 1-8. [Abstract] [Full-text]
  12. Amphipathic peptide-based fusion peptides and immunoconjugates for the targeted ablation of prostate cancer cells.
    Cancer Res, 67(13): 6368-75. [Abstract] [Full-text]
  13. Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha.
    Cancer Res, 67(13): 6263-9. [Abstract] [Full-text]
  14. Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells.
    Cancer Res, 67(13): 6192-203. [Abstract] [Full-text]
  15. Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin.
    Cancer Res, 67(13): 6183-91. [Abstract] [Full-text]
  16. O-glycosylation regulates LNCaP prostate cancer cell susceptibility to apoptosis induced by galectin-1.
    Cancer Res, 67(13): 6155-62. [Abstract] [Full-text]
  17. MicroRNA expression profiling in prostate cancer.
    Cancer Res, 67(13): 6130-5. [Abstract] [Full-text]
  18. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development.
    Cancer Res, 67(13): 6083-91. [Abstract] [Full-text]
  19. Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response.
    Cancer Res, 67(13): 6022-5. [Abstract] [Full-text]
  20. Prostate cancer testing following a negative prostate biopsy: over testing the elderly.
    J Gen Intern Med, 22(8): 1139-43. [Abstract] [Full-text]
  21. Reconsidering the use of the International Index of Erectile Function questionnaire in evaluating the preoperative erectile function status of patients undergoing radical prostatectomy.
    BJU Int, 100(2): 368-70. [Abstract] [Full-text]
  22. Effect of low dose-rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: analysis at > or = 7 years of follow-up.
    BJU Int, 100(2): 362-7. [Abstract] [Full-text]
  23. Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer.
    BJU Int, 100(2): 315-9. [Abstract] [Full-text]
  24. Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer.
    BJU Int, 100(2): 303-9. [Abstract] [Full-text]
  25. Persistent expression of Aurora-A after neoadjuvant hormonal therapy as a predictor of a poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer.
    BJU Int, 100(2): 310-4. [Abstract] [Full-text]
  26. Cryotherapy for the prostate: an in vitro and clinical study of two new developments; advanced cryoneedles and a temperature monitoring system.
    BJU Int, 100(2): 295-302. [Abstract] [Full-text]
  27. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
    BJU Int, 100(2): 274-80. [Abstract] [Full-text]
  28. Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: an important role for SAPK signalling in prostatic neoplasia.
    J Pathol, 212(4): 386-94. [Abstract] [Full-text]
  29. Overexpression and gene amplification of BAG-1L in hormone-refractory prostate cancer.
    J Pathol, 212(4): 395-401. [Abstract] [Full-text]
  30. Phyto-oestrogens and risk of prostate cancer in Scottish men.
    Br J Nutr, 98(2): 388-96. [Abstract] [Full-text]
  31. The prostate needle biopsy gun: busting a myth.
    J Urol, 178(2): 683-5. [Abstract] [Full-text]
  32. Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition.
    J Urol, 178(2): 692-6. [Abstract] [Full-text]
  33. Erectile function outcome reporting after clinically localized prostate cancer treatment.
    J Urol, 178(2): 597-601. [Abstract] [Full-text]
  34. New insights into the pathogenesis of penile shortening after radical prostatectomy and the role of postoperative sexual function.
    J Urol, 178(2): 602-7. [Abstract] [Full-text]
  35. Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE.
    J Urol, 178(2): 529-34; discussion 534. [Abstract] [Full-text]
  36. Effect of statin therapy on early return of potency after nerve sparing radical retropubic prostatectomy.
    J Urol, 178(2): 613-6. [Abstract] [Full-text]
  37. Analysis linking UCLA PCI with Expanded Prostate Cancer Index Composite: an evaluation of health related quality of life in Japanese men with localized prostate cancer.
    J Urol, 178(2): 473-7; discussion 477. [Abstract] [Full-text]
  38. Surgical outcomes for men undergoing laparoscopic radical prostatectomy after transurethral resection of the prostate.
    J Urol, 178(2): 483-7; discussion 487. [Abstract] [Full-text]
  39. A direct comparison of robotic assisted versus pure laparoscopic radical prostatectomy: a single institution experience.
    J Urol, 178(2): 478-82. [Abstract] [Full-text]
  40. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
    J Urol, 178(2): 493-9; discussion 499. [Abstract] [Full-text]
  41. Comparison of contrast enhanced color Doppler targeted biopsy to conventional systematic biopsy: impact on Gleason score.
    J Urol, 178(2): 464-8; discussion 468. [Abstract] [Full-text]
  42. Impact of nerve sparing technique on patient self-assessed outcomes after radical perineal prostatectomy.
    J Urol, 178(2): 488-92; discussion 492. [Abstract] [Full-text]
  43. Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era?
    J Urol, 178(2): 459-63; discussion 463. [Abstract] [Full-text]
  44. Effect of intraprostatic local anesthesia during transrectal ultrasound guided prostate biopsy: comparison of 3 methods in a randomized, double-blind, placebo controlled trial.
    J Urol, 178(2): 469-72; discussion 472. [Abstract] [Full-text]
  45. Racial differences in serum selenium concentration: analysis of US population data from the Third National Health and Nutrition Examination Survey.
    Am J Epidemiol, 166(3): 280-8. [Abstract] [Full-text]
  46. Reduced neutron production through use of a flattening-filter-free accelerator.
    Int J Radiat Oncol Biol Phys, 68(4): 1260-4. [Abstract] [Full-text]
  47. Quantifying appropriate PTV setup margins: analysis of patient setup fidelity and intrafraction motion using post-treatment megavoltage computed tomography scans.
    Int J Radiat Oncol Biol Phys, 68(4): 1222-8. [Abstract] [Full-text]
  48. Irradiation of human prostate cancer cells increases uptake of antisense oligodeoxynucleotide.
    Int J Radiat Oncol Biol Phys, 68(4): 1161-8. [Abstract] [Full-text]
  49. Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo.
    Int J Radiat Oncol Biol Phys, 68(4): 1151-60. [Abstract] [Full-text]
  50. Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations.
    Int J Radiat Oncol Biol Phys, 68(4): 1065-71. [Abstract] [Full-text]
  51. Positional stability of electromagnetic transponders used for prostate localization and continuous, real-time tracking.
    Int J Radiat Oncol Biol Phys, 68(4): 1199-206. [Abstract] [Full-text]
  52. Postimplant dosimetry using a Monte Carlo dose calculation engine: a new clinical standard.
    Int J Radiat Oncol Biol Phys, 68(4): 1190-8. [Abstract] [Full-text]
  53. Perineural invasion is a marker for pathologically advanced disease in localized prostate cancer.
    Int J Radiat Oncol Biol Phys, 68(4): 1059-64. [Abstract] [Full-text]
  54. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer.
    Int J Radiat Oncol Biol Phys, 68(4): 1053-8. [Abstract] [Full-text]
  55. Doctors' and patients' preferences for participation and treatment in curative prostate cancer radiotherapy.
    J Clin Oncol, 25(21): 3096-100. [Abstract] [Full-text]
  56. Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202.
    J Clin Oncol, 25(21): 3082-9. [Abstract] [Full-text]
  57. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
    J Clin Oncol, 25(21): 3076-81. [Abstract] [Full-text]
  58. The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens.
    Hum Pathol, 38(8): 1207-11. [Abstract] [Full-text]
  59. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer.
    AJR Am J Roentgenol, 189(2): 323-8. [Abstract] [Full-text]
  60. Hormonal regulation of IGFBP-2 proteolysis is attenuated with progression to androgen insensitivity in the LNCaP progression model.
    J Cell Physiol, 213(1): 261-8. [Abstract] [Full-text]
  61. A common genetic risk factor for colorectal and prostate cancer.
    Nat Genet, 39(8): 954-6. [Abstract] [Full-text]
  62. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes.
    Nat Genet, 39(8): 977-83. [Abstract] [Full-text]
  63. Glyceraldehyde-3-phosphate dehydrogenase enhances transcriptional activity of androgen receptor in prostate cancer cells.
    J Biol Chem, 282(31): 22651-61. [Abstract] [Full-text]
  64. My approach to intraductal lesions of the prostate gland.
    J Clin Pathol, 60(8): 856-65. [Abstract] [Full-text]
  65. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
    Int J Cancer, 121(7): 1424-32. [Abstract] [Full-text]
  66. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study.
    Int J Cancer, 121(7): 1571-8. [Abstract] [Full-text]
  67. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies.
    J Clin Oncol, 25(22): 3281-7. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2013 Prostate Cancer Research Today. All Rights Reserved.



Prostate Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 10 (2013)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)



Prostate Cancer Books

PROSTATE CANCER MEETS THE PROTON BEAM: A Patient's Experience

PROSTATE CANCER MEETS THE PROTON BEAM: A Patient's Experience